CG Oncology, Inc. (CGON)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $63.96
- As of
Kresmion compiles this page from CGON's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
CG Oncology, Inc. (CGON): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
See the full CGON dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CGON on one page. Preview it with sample data, then open it live with a free account.
Preview the CGON dossierActive events for CGON
- mediumEarnings below estimates
Q2-2026: Missed consensus by 32.8%, EPS $-0.90 vs $-0.6776 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 73% of CGON (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +310% to CGON (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 64% of CGON (2026Q2)
- high13F: large increase
D. E. Shaw & Co., Inc. added +92% to CGON (2026Q2)
FREE, NO ACCOUNT
Every event on CGON, as it fires
You are seeing 5 of 10 events recorded on CGON since 2026-05-16.
The five above all landed on 2026-08-16. The other 5 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CGON (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 156944100 · 2026Q2 | $6.4M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CGON
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CGON against its peers
CGON's operating margin of -4722.1% ranks in the 17th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | CGON | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 4.0M USD | 264M USD | 22 | 15 |
| Gross margin | n/a | 89.7% | n/a | 5 |
| Operating margin | -4722.1% | -70.8% | 17 | 14 |
| Net margin | -3985.0% | -72.0% | 17 | 14 |
| Return on equity | -21.4% | -35.2% | 76 | 22 |
Peers (24): COGT, MIRM, BLTE, MANE, IMVT, ERAS, KOD, SRRK, PTCT, APLS.D, CRSP, CNTA.D, DFTX, RYTM, ORKA, LGND, TVTX, IOVA, GRAL, DNTH, EWTX, LEGN, RLAY, IONS. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (CGON: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CGON on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CGON for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.